HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

CI1033 (CI 1033)

structure in first source
Also Known As:
CI 1033; CI-1033; Canertinib; PD 183805; PD-183805; PD183805
Networked: 53 relevant articles (4 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Lenehan, Peter F: 7 articles (09/2007 - 06/2002)
2. Eiseman, Irene A: 4 articles (09/2007 - 06/2002)
3. Fry, David W: 4 articles (06/2005 - 05/2002)
4. Walz, Thomas M: 3 articles (10/2011 - 02/2010)
5. Hallbeck, Anna-Lotta: 3 articles (10/2011 - 02/2010)
6. Trinks, Cecilia: 3 articles (10/2011 - 02/2010)
7. Eiseman, Irene: 3 articles (05/2007 - 05/2005)
8. Olson, Stephen C: 3 articles (05/2007 - 05/2005)
9. Rak, Janusz: 2 articles (10/2015 - 07/2010)
10. Christensen, James G: 2 articles (02/2012 - 06/2005)

Related Diseases

1. Neoplasms (Cancer)
2. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
3. Pneumonia (Pneumonitis)
4. Infection
5. Ovarian Neoplasms (Ovarian Cancer)

Related Drugs and Biologics

1. erlotinib (CP 358,774)
2. Phosphotransferases (Kinase)
3. gefitinib (Iressa)
4. Epidermal Growth Factor Receptor (EGF Receptor)
5. EKB 569
6. lapatinib (GW572016)
7. N- (4- bromo- 2- fluorophenyl)- 6- methoxy- 7- ((1- methylpiperidin- 4- yl)methoxy)quinazolin- 4- amine (ZD6474)
8. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9. Interleukin-8 (Interleukin 8)
10. Biological Markers (Surrogate Marker)

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Drug Therapy (Chemotherapy)
3. Oral Administration